Literature DB >> 20959327

NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis.

Francesco Del Galdo1, Peter J Wermuth, Sankar Addya, Paolo Fortina, Sergio A Jimenez.   

Abstract

OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is a generalised fibrotic disorder occurring in certain individuals with renal insufficiency exposed to gadolinium-based contrast agents (GdBCA) for MRI. Histopathological examination of affected tissues shows increased numbers of activated macrophages. To elucidate the mechanisms responsible for macrophage activation, the effects of the GdBCA Omniscan on normal human macrophage global gene expression, chemokine production and nuclear factor κB (NFκB) activation was examined.
METHODS: Normal human monocyte-derived macrophages were incubated with Omniscan (50 mM) and their gene expression analysed by microarrays and real-time PCR. Macrophage chemokine production was assayed by multiplex ELISA. NFκB activation was assessed by NFκB nuclear localisation and quantitation of intracellular levels of inducible nitric oxide synthase (iNOS) protein. A specific cell-permeable NFκB peptide inhibitor was used to abrogate NFκB stimulation of chemokine and iNOS protein levels. CCL8/MCP-2 in affected skin of patients with NSF was examined by indirect immunofluorescence.
RESULTS: Omniscan caused a profound change in the transcriptome of differentiated human normal macrophages in vitro, including a large increase in the expression of genes encoding CC and CXC chemokines. It induced rapid nuclear localisation of NFκB and stimulation of iNOS protein levels and chemokine production which were blocked by an NFκB inhibitory peptide. CCL8/MCP-2, the most upregulated chemokine following in vitro macrophage exposure to Omniscan, was strongly increased in NSF-affected skin.
CONCLUSION: The GdBCA Omniscan induces potent stimulation of macrophage gene expression, NFκB activation and increased NFκB-mediated production of CC and CXC chemokines and iNOS. These alterations may play a crucial role in the pathogenesis of NSF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959327      PMCID: PMC6658210          DOI: 10.1136/ard.2010.134858

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  39 in total

1.  Array-based ELISAs for high-throughput analysis of human cytokines.

Authors:  M D Moody; S W Van Arsdell; K P Murphy; S F Orencole; C Burns
Journal:  Biotechniques       Date:  2001-07       Impact factor: 1.993

2.  Nephrogenic fibrosing dermopathy.

Authors:  S E Cowper; L D Su; J Bhawan; H S Robin; P E LeBoit
Journal:  Am J Dermatopathol       Date:  2001-10       Impact factor: 1.533

3.  The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum.

Authors:  S J Leibovich; R Ross
Journal:  Am J Pathol       Date:  1975-01       Impact factor: 4.307

4.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

5.  Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex.

Authors:  M J May; F D'Acquisto; L A Madge; J Glöckner; J S Pober; S Ghosh
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

6.  Macrophage infiltration in the skin of patients with systemic sclerosis.

Authors:  O Ishikawa; H Ishikawa
Journal:  J Rheumatol       Date:  1992-08       Impact factor: 4.666

7.  Nephrogenic fibrosing dermopathy with systemic involvement.

Authors:  William W Ting; Mary Seabury Stone; Kathi C Madison; Kevin Kurtz
Journal:  Arch Dermatol       Date:  2003-07

8.  Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure.

Authors:  Richard D Swartz; Leslie J Crofford; Sem H Phan; Robert W Ike; Lyndon D Su
Journal:  Am J Med       Date:  2003-05       Impact factor: 4.965

9.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

Authors:  Julian M Mackay-Wiggan; David J Cohen; Mark A Hardy; Elizabeth H Knobler; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

10.  Safety of gadolinium contrast agent in hemodialysis patients.

Authors:  S Okada; K Katagiri; T Kumazaki; H Yokoyama
Journal:  Acta Radiol       Date:  2001-05       Impact factor: 1.701

View more
  19 in total

Review 1.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

2.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

3.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

4.  Stimulation of fibroblast proliferation by insoluble gadolinium salts.

Authors:  Katherine Bleavins; Patricia Perone; Madhav Naik; Muneeb Rehman; Muhammad N Aslam; Michael K Dame; Sasha Meshinchi; Narasimharao Bhagavathula; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-09-01       Impact factor: 3.738

5.  Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents.

Authors:  P J Wermuth; S A Jimenez
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

6.  Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

Authors:  E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2020-10-11       Impact factor: 4.304

7.  Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation.

Authors:  Christian Schmidt-Lauber; Lukas Bossaller; Hani H Abujudeh; Gregory I Vladimer; Anette Christ; Katherine A Fitzgerald; Eicke Latz; Ellen M Gravallese; Ann Marshak-Rothstein; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2014-06-09       Impact factor: 19.103

8.  Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis.

Authors:  Viktor R Drel; Chunyan Tan; Jeffrey L Barnes; Yves Gorin; Doug-Yoon Lee; Brent Wagner
Journal:  FASEB J       Date:  2016-05-24       Impact factor: 5.191

Review 9.  Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance.

Authors:  Theresa Reiter; Oliver Ritter; Martin R Prince; Peter Nordbeck; Christoph Wanner; Eike Nagel; Wolfgang Rudolf Bauer
Journal:  J Cardiovasc Magn Reson       Date:  2012-05-20       Impact factor: 5.364

10.  Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.

Authors:  Stephanie L Barnes; Jennifer G Whisenant; Mary E Loveless; Thomas E Yankeelov
Journal:  Pharmaceutics       Date:  2012       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.